Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Byrna Technologies Inc (BYRN) Price & Performance

ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.

Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.

BYRN trades at $3.865, down 1.9% today, with a bearish technical signal from moving averages and oscillators. Recent Q2 2026 results showed a significant revenue decline of 42.5% year-over-year and a net loss of $0.44 per share, missing estimates. The company faces challenges in sales and marketing effectiveness but is undertaking strategic initiatives including a recent acquisition and marketing overhaul to revive growth.

The outlook remains cautious due to persistent profitability issues and negative cash flow trends. While analyst consensus is predominantly Buy (71%), reflecting long-term potential in the less-lethal defense market, near-term risks from execution missteps and competitive pressures warrant careful monitoring. Investor sentiment is mixed amid ongoing operational reset efforts.